

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT3612875

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
TRIPEX PHARMACEUTICALS, LLC	10/01/2015

RECEIVING PARTY DATA

Name:	RAPTOR PHARMACEUTICALS INC
Street Address:	7 HAMILTON LANDING, SUITE 100
City:	NOVATO
State/Country:	CALIFORNIA
Postal Code:	94949

PROPERTY NUMBERS Total: 26

Property Type	Number
Patent Number:	7838532
Patent Number:	8357696
Patent Number:	8524734
Patent Number:	8546423
Patent Number:	8524735
Application Number:	14012307
Application Number:	60682530
Application Number:	60696160
Application Number:	14134348
Application Number:	60977283
Application Number:	61103496
Patent Number:	8815838
Application Number:	14333583
Application Number:	60977287
Application Number:	61103501
Application Number:	61172625
Application Number:	61249231
Application Number:	61240092
Application Number:	13398310
Application Number:	61235319

PATENT

Property Type	Number
Application Number:	61240749
Application Number:	61249228
Application Number:	13398507
Application Number:	13278706
Application Number:	13412423
Patent Number:	8629139

CORRESPONDENCE DATA

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 617 542-6000

Email: tjoel@mintz.com

Correspondent Name: MINTZ LEVIN

Address Line 1: ONE FINANCIAL CENTER

Address Line 4: BOSTON, MASSACHUSETTS 02111

ATTORNEY DOCKET NUMBER:	49048-500
NAME OF SUBMITTER:	EDWARD D. GRIEFF
SIGNATURE:	/Edward D. Grieff/
DATE SIGNED:	11/12/2015
	This document serves as an Oath/Declaration (37 CFR 1.63).

Total Attachments: 21

source=Assignment TripetoRaptor#page1.tif
source=Assignment TripetoRaptor#page2.tif
source=Assignment TripetoRaptor#page3.tif
source=Assignment TripetoRaptor#page4.tif
source=Assignment TripetoRaptor#page5.tif
source=Assignment TripetoRaptor#page6.tif
source=Assignment TripetoRaptor#page7.tif
source=Assignment TripetoRaptor#page8.tif
source=Assignment TripetoRaptor#page9.tif
source=Assignment TripetoRaptor#page10.tif
source=Assignment TripetoRaptor#page11.tif
source=Assignment TripetoRaptor#page12.tif
source=Assignment TripetoRaptor#page13.tif
source=Assignment TripetoRaptor#page14.tif
source=Assignment TripetoRaptor#page15.tif
source=Assignment TripetoRaptor#page16.tif
source=Assignment TripetoRaptor#page17.tif
source=Assignment TripetoRaptor#page18.tif
source=Assignment TripetoRaptor#page19.tif
source=Assignment TripetoRaptor#page20.tif
source=Assignment TripetoRaptor#page21.tif

PATENT ASSIGNMENT

This Patent Assignment (this “Assignment”) is being executed and delivered as of October 2, 2015, by and between Tripex Pharmaceuticals, LLC, a Delaware limited liability company having offices at P.O. Box 230486, Encinitas, CA 92023 (the “Seller”), to and for the benefit of Raptor Pharmaceuticals Inc., a Delaware corporation having offices at 7 Hamilton Landing, Suite 100, Novato, CA 94949 (the “Purchaser”). Capitalized terms used but not defined in this Assignment shall have the meanings given to them in the Purchase Agreement (as defined below).

RECITALS

A. The Purchaser Raptor Pharmaceutical Corp., a Delaware corporation (“Parent”), and the Seller have entered into an Amended and Restated Asset Purchase Agreement, dated as of October 2, 2015 (the “Purchase Agreement”), whereby, upon the terms and subject to the conditions set forth therein, the Seller has agreed to sell, transfer, convey, assign and deliver the Transferred Patents (as defined below) to the Purchaser.

B. The Seller is the owner of all the Patents (including the right, title and interest in and to such Patents) included in the Transferred IP (including, without limitation, the Patents listed on Schedule 1 hereto) and the other items listed in Section 1 below (the “Transferred Patents”).

C. This Assignment is being delivered by the Seller to the Purchaser pursuant to Section 7.5(j) of the Purchase Agreement.

ASSIGNMENT

1. For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Seller, on behalf of itself and its Affiliates, hereby assigns to the Purchaser, free and clear of any Encumbrances (except for Permitted Encumbrances) on the terms set forth in the Purchase Agreement, all of the following Assets (including the entire right, title, and interest therein and thereto throughout the world):

- (a) the Patents included in the Transferred IP;
 - (b) any Patents that claim priority to any Patent included in the Transferred IP (including, without limitation, all present and future divisions, continuations, continuations-in-part, reissues, reexaminations, renewals and extensions thereof, all foreign counterparts to any of the foregoing); and
 - (c) any other rights in the inventions described or disclosed in any Patents in clauses “(a)” and “(b)”;
- (all of the Assets in clauses “(a)”, “(b)” and “(c)”, collectively, the “Transferred Patents”).

2. For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Seller, on behalf of itself and its Affiliates, hereby sells, assigns, transfers, conveys and delivers to the Purchaser, free and clear of any Encumbrances (except for Permitted Encumbrances) on the terms and subject to the conditions set forth in the Purchase Agreement, all of the following Assets (including the entire right, title, and interest therein and thereto throughout the world):

- (a) all rights to causes of action and remedies related to the Transferred Patents, including without limitation, the right to sue for, among other things, damages and injunctive relief for any past, present or future infringement, violation, dilution or other unauthorized use of any of the Transferred Patents;

- (b) all rights to receive income, royalties, damages, payments or other consideration with respect to the Transferred Patents;
- (c) all rights to prosecute and maintain the Transferred Patents; and
- (d) all other rights and interests arising out of, in connection with or in relation to the Transferred Patents.

3. Notwithstanding anything to the contrary set forth in this Assignment, nothing contained in this Assignment is intended to provide any rights to the Seller, Parent or the Purchaser beyond those rights expressly provided to the Seller, Parent or the Purchaser, respectively, in the Purchase Agreement. Nothing contained in this Assignment is intended to impose any obligations or other Liabilities on Parent, the Purchaser or the Seller beyond those obligations and other Liabilities expressly imposed on Parent, the Purchaser or the Seller, respectively, in the Purchase Agreement. Nothing contained in this Assignment is intended to limit any of the rights or remedies available to Parent and/or the Purchaser under the Purchase Agreement. In the event of any conflict, inconsistency or other difference between the Purchase Agreement and this Assignment, the provisions of the Purchase Agreement shall be deemed to govern and control in all circumstances.

4. Notwithstanding anything to the contrary set forth in this Assignment, nothing set forth in this Assignment shall result in or be deemed to constitute an actual or purported assumption by Parent and/or the Purchaser of, or an agreement by Parent and/or the Purchaser to assume or undertake any responsibility for paying, discharging or otherwise performing, any Liability, including, without limitation, any Liability of the Seller, any Affiliate of the Seller, any Seller Predecessor or any other Person.

5. The Seller hereby authorizes the Commissioner of Patents of the United States, and the empowered official of any country or countries foreign to the United States whose duty it is to issue Patents and title thereto, to record this Assignment and to issue any Patent included in the Transferred Patents as the property of the Purchaser, its successors, assigns or legal representatives in accordance with the terms of this instrument.

6. This Assignment may be executed in two or more counterparts (including by facsimile or electronic transmission), all of which shall be considered one and the same agreement, and shall become effective when one counterpart has been signed by each party and delivered to the other parties hereto. In the event that any signature to this Assignment is delivered by facsimile transmission or by e-mail delivery of a portable document format (.pdf or similar format) data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or “.pdf” signature page were an original thereof.

7. This Assignment shall be construed in accordance with, and governed in all respects by, the internal laws of the State of Delaware (without giving effect to principles of conflicts of laws).

[Signature page follows]

IN WITNESS WHEREOF, the Seller has caused this Assignment to be executed and delivered as a sealed instrument as of the date first written above.

TRIPEX PHARMACEUTICALS, LLC

By: [Signature]

Name: Daniel Burgos


Title: President & CEO

State of Calif.

County of San Diego

Signed before me this 1 day of Oct., 2015

[Signature]
Notary Public



RAPTOR PHARMACEUTICALS INC.

By: _____

Name: _____

Title: _____

Date: _____

IN WITNESS WHEREOF, the Seller has caused this Assignment to be executed and delivered as a sealed instrument as of the date first written above.

TRIPEX PHARMACEUTICALS, LLC


By: _____
Name: _____
Title: _____

State of _____
County of _____

Signed before me this _____ day of _____, 2015

Notary Public

RAPTOR PHARMACEUTICALS INC.

By: 
Name: Michael P. Smith
Title: CFO
Date: October 2, 2015

[SIGNATURE PAGE TO PATENT ASSIGNMENT]

PATENT
REEL: 037102 FRAME: 0578

SCHEDULE 1

TRANSFERRED PATENT RIGHTS

PATENT

REEL: 037102 FRAME: 0579

TRANSFERRED IP

Patent assets

Docket	Country	Internal Reference No.	Title	Serial No.	Patent No.
1914-53	US	MPEX-028	AEROSOLIZED FLUOROQUINOLONE S AND USES THEREOF	11/436875	7838532
1914-53	AU	MPEX-028 AU	AEROSOLIZED FLUOROQUINOLONE S AND USES THEREOF	2006247053	2006247053
1914-53	AU	MPEX-028 AU DIV	AEROSOLIZED FLUOROQUINOLONE S AND USES THEREOF	2013203605	
1914-53	BR	MPEX-028 BR	AEROSOLIZED FLUOROQUINOLONE S AND USES THEREOF	PI 0707904-4	
1914-53	CA	MPEX-028 CA	AEROSOLIZED FLUOROQUINOLONE S AND USES THEREOF	2608273	
1914-53	CA	MPEX-028 CA DIV	AEROSOLIZED FLUOROQUINOLONE S AND USES THEREOF		
1914-53	CN	MPEX-028 CN	AEROSOLIZED FLUOROQUINOLONE S AND USES THEREOF	200680026156.0	
1914-53	CN	MPEX-028 CN DIV	AEROSOLIZED FLUOROQUINOLONE S AND USES THEREOF	201410195250.5	
1914-53	US	MPEX-028 CON	AEROSOLIZED FLUOROQUINOLONE S AND USES THEREOF	12/695981	8357696
1914-53	US	MPEX-028 DIV A	AEROSOLIZED FLUOROQUINOLONE S AND USES THEREOF	12/604324	8524734
1914-53	US	MPEX-028 DIV B	AEROSOLIZED FLUOROQUINOLONE S AND USES	12/604340	8546423

Docket	Country	Internal Reference No.	Title	Serial No.	Patent No.
			THEREOF		
1914-53	US	MPEX-028 DIV B CON	AEROSOLIZED FLUOROQUINOLONE S AND USES THEREOF	14/012307	
1914-53	US	MPEX-028 DIV C	AEROSOLIZED FLUOROQUINOLONE S AND USES THEREOF	12/604347	8524735
1914-53	EP	MPEX-028 EP	AEROSOLIZED FLUOROQUINOLONE S AND USES THEREOF	6760146.8	
1914-53	EP	MPEX-028 EP DIV	AEROSOLIZED FLUOROQUINOLONE S AND USES THEREOF	12007354.9	
1914-53	HK	MPEX-028 HK	AEROSOLIZED FLUOROQUINOLONE S AND USES THEREOF	08109955.6	
1914-53	HK	MPEX-028 HK DIV	AEROSOLIZED FLUOROQUINOLONE S AND USES THEREOF	13113008.8	
1914-53	IL	MPEX-028 IL	AEROSOLIZED FLUOROQUINOLONE S AND USES THEREOF	187346	
1914-53	IL	MPEX-028 IL DIV	AEROSOLIZED FLUOROQUINOLONE S AND USES THEREOF	227521	
1914-53	IL	MPEX-028 IL DIV B	AEROSOLIZED FLUOROQUINOLONE S AND USES THEREOF	239821	
1914-53	IN	MPEX-028 IN	AEROSOLIZED FLUOROQUINOLONE S AND USES THEREOF	9605/DELNP/2007	
1914-53	JP	MPEX-028 JP	AEROSOLIZED FLUOROQUINOLONE S AND USES THEREOF	2008-512525	5279487

Docket	Country	Internal Reference No.	Title	Serial No.	Patent No.
1914-53	JP	MPEX-028 JP DIV	AEROSOLIZED FLUOROQUINOLONE S AND USES THEREOF	2013-2399	5690853
1914-53	KR	MPEX-028 KR	AEROSOLIZED FLUOROQUINOLONE S AND USES THEREOF	10-2007-7029629	10-1488403
1914-53	KR	MPEX-028 KR DIV	AEROSOLIZED FLUOROQUINOLONE S AND USES THEREOF	10-2014-7002452	
1914-53	KR	MPEX-028 KR DIV 2	AEROSOLIZED FLUOROQUINOLONE S AND USES THEREOF	10-2014-7016750	101488402
1914-53	MX	MPEX-028 MX	AEROSOLIZED FLUOROQUINOLONE S AND USES THEREOF	MX/a/2007/014316	288398
1914-53	MX	MPEX-028 MX DIV	AEROSOLIZED FLUOROQUINOLONE S AND USES THEREOF	MX/a/2011/007566	3288964
1914-53	MX	MPEX-028 MX DIV 2	AEROSOLIZED FLUOROQUINOLONE S AND USES THEREOF	MX/a/2015/003856	
1914-53	NZ	MPEX-028 NZ	AEROSOLIZED FLUOROQUINOLONE S AND USES THEREOF	563417	563417
1914-53	NZ	MPEX-028 NZ DIV	AEROSOLIZED FLUOROQUINOLONE S AND USES THEREOF	591509	591509
1914-53	NZ	MPEX-028 NZ DIV II	AEROSOLIZED FLUOROQUINOLONE S AND USES THEREOF	597290	597290
1914-53	WO	MPEX-028 PCT	AEROSOLIZED FLUOROQUINOLONE S AND USES THEREOF	PCT/US06/01935	
1914-53	WO	MPEX-028 PCT 2	AEROSOLIZED FLUOROQUINOLONE S AND USES	PCT/US07/003649	

Docket	Country	Internal Reference No.	Title	Serial No.	Patent No.
			THEREOF		
1914-53	US	MPEX-028 PRO	AEROSOLIZED FLUOROQUINOLONE S AND USES THEREOF	60/682530	
1914-53	US	MPEX-028 PRO II	AEROSOLIZED FLUOROQUINOLONE S AND USES THEREOF	60/696160	
1914-53	RU	MPEX-028 RU	AEROSOLIZED FLUOROQUINOLONE S AND USES THEREOF	2007146972	2428986
1914-53	RU	MPEX-028 RU DIV	AEROSOLIZED FLUOROQUINOLONE S AND USES THEREOF	2011118619	
1914-53	SG	MPEX-028 SG	AEROSOLIZED FLUOROQUINOLONE S AND USES THEREOF	200717702-5	137352
1914-53	SG	MPEX-028 SG DIV	AEROSOLIZED FLUOROQUINOLONE S AND USES THEREOF	2012-02482-4	181278
1914-53	ZA	MPEX-028 ZA	AEROSOLIZED FLUOROQUINOLONE S AND USES THEREOF	2007/10745	2007/10745
1914-55	US	MPEX-051	TOPICAL USE OF LEVOFLOXACIN FOR REDUCING LUNG INFLAMMATION	12/574666	8629139
1914-55	BR	MPEX-051 BR	TOPICAL USE OF LEVOFLOXACIN FOR REDUCING LUNG INFLAMMATION		
1914-55	CA	MPEX-051 CA	INHALATION OF LEVOFLOXACIN FOR REDUCING LUNG INFLAMMATION	2739893	
1914-55	CN	MPEX-051 CN	INHALATION OF LEVOFLOXACIN FOR REDUCING LUNG INFLAMMATION	200980142471.3	102325532B

Docket	Country	Internal Reference No.	Title	Serial No.	Patent No.
1914-55	MO	2257-4 CN	INHALATION OF LEVOFLOXACIN FOR REDUCING LUNG INFLAMMATION	J/001882	
1914-55	US	MPEX-051 CON	TOPICAL USE OF LEVOFLOXACIN FOR REDUCING LUNG INFLAMMATION	14/134348	
1914-55	EP	MPEX-051 EP	-INHALATION OF LEVOFLOXACIN FOR REDUCING LUNG INFLAMMATION	9740571.6	-
1914-55	HK	MPEX-051 HK	TOPICAL USE OF LEVOFLOXACIN FOR REDUCING LUNG INFLAMMATION	12100733.8	
1914-55	IL	MPEX-051 IL	TOPICAL USE OF LEVOFLOXACIN FOR REDUCING LUNG INFLAMMATION	212189	
1914-55	JP	MPEX-051 JP	TOPICAL USE OF LEVOFLOXACIN FOR REDUCING LUNG INFLAMMATION	2011-531125	
1914-55	JP	MPEX-051 JP DIV	TOPICAL USE OF LEVOFLOXACIN FOR REDUCING LUNG INFLAMMATION	2014-95077	
1914-55	JP	MPEX-051 JP DIV II	INHALATION OF LEVOFLOXACIN FOR REDUCING LUNG INFLAMMATION	2014-208156	
1914-55	MX	MPEX-051 MX	TOPICAL USE OF LEVOFLOXACIN FOR REDUCING LUNG INFLAMMATION	MX/a/2011/003744	
1914-55	WO	MPEX-051 PCT	TOPICAL USE OF LEVOFLOXACIN FOR REDUCING LUNG INFLAMMATION	PCT/US09/059740	
1914-55	US	MPEX-051 PRO	TOPICAL USE OF LEVOFLOXACIN FOR REDUCING LUNG INFLAMMATION	60/977283	
1914-55	US	MPEX-051 PRO 2	TOPICAL USE OF LEVOFLOXACIN FOR REDUCING LUNG	61/103496	

Docket	Country	Internal Reference No.	Title	Serial No.	Patent No.
			INFLAMMATION		
1914-55	SG	MPEX-051 SG	INHALATION OF LEVOFLOXACIN FOR REDUCING LUNG INFLAMMATION	201102457-7	
1914-56	US	MPEX-052	AEROSOL FLUOROQUINOLONE FORMULATIONS FOR IMPROVED PHARMACOKINETICS	12/574680	8815838
1914-56	AU	MPEX-052 AU	AEROSOL FLUOROQUINOLONE FORMULATIONS FOR IMPROVED PHARMACOKINETICS	2009302478	
1914-56	BR	MPEX-052 BR	AEROSOL FLUOROQUINOLONE FORMULATIONS FOR IMPROVED PHARMACOKINETICS	PI 0920026-6	
1914-56	CA	MPEX-052 CA	AEROSOL FLUOROQUINOLONE FORMULATIONS FOR IMPROVED PHARMACOKINETICS	2739897	
1914-56	CN	MPEX-052 CN	AEROSOL FLUOROQUINOLONE FORMULATIONS FOR IMPROVED PHARMACOKINETICS	200980143627.X	
1914-56	US	MPEX-052 CON	AEROSOL FLUOROQUINOLONE FORMULATIONS FOR IMPROVED PHARMACOKINETICS	14/333583	
1914-56	EP	MPEX-052 EP	AEROSOL FLUOROQUINOLONE FORMULATIONS FOR IMPROVED PHARMACOKINETICS	09793326.1	
1914-56	HK	MPEX-052 HK	AEROSOL FLUOROQUINOLONE FORMULATIONS FOR IMPROVED PHARMACOKINETICS	12100656.1	

Docket	Country	Internal Reference No.	Title	Serial No.	Patent No.
1914-56	IL	MPEX-052 IL	AEROSOL FLUOROQUINOLONE FORMULATIONS FOR IMPROVED PHARMACOKINETICS	212190	
1914-56	IN	MPEX-052 IN	AEROSOL FLUOROQUINOLONE FORMULATIONS FOR IMPROVED PHARMACOKINETICS	3391/DELNP/2011	
1914-56	JP	MPEX-052 JP	AEROSOL FLUOROQUINOLONE FORMULATIONS FOR IMPROVED PHARMACOKINETICS	2011-531126	
1914-56	JP	MPEX-052 JP DIV	AEROSOL FLUOROQUINOLONE FORMULATIONS FOR IMPROVED PHARMACOKINETICS	2015-63052	
1914-56	KR	MPEX-052 KR	AEROSOL FLUOROQUINOLONE FORMULATIONS FOR IMPROVED PHARMACOKINETICS	10-2011-7010639	
1914-56	MX	MPEX-052 MX	AEROSOL FLUOROQUINOLONE FORMULATIONS FOR IMPROVED PHARMACOKINETICS	MX/a/2011/003745	
1914-56	NZ	MPEX-052 NZ	AEROSOL FLUOROQUINOLONE FORMULATIONS FOR IMPROVED PHARMACOKINETICS	592717	592717
1914-56	NZ	MPEX-052 NZ DIV	AEROSOL FLUOROQUINOLONE FORMULATIONS FOR IMPROVED PHARMACOKINETICS	607408	607408
1914-56	NZ	MPEX-052 NZ DIV 2	AEROSOL FLUOROQUINOLONE FORMULATIONS FOR IMPROVED PHARMACOKINETICS	631469	
1914-56	WO	MPEX-052 PCT	AEROSOL FLUOROQUINOLONE FORMULATIONS FOR	PCT/US09/059744	

Docket	Country	Internal Reference No.	Title	Serial No.	Patent No.
			IMPROVED PHARMACOKINETICS		
1914-56	US	MPEX-052 PRO	AEROSOL FLUOROQUINOLONE FORMULATIONS FOR IMPROVED PHARMACOKINETICS	60/977287	
1914-56	US	MPEX-052 PRO 2	AEROSOL FLUOROQUINOLONE FORMULATIONS FOR IMPROVED PHARMACOKINETICS	61/103501	
1914-56	SG	MPEX-052 SG	AEROSOL FLUOROQUINOLONE FORMULATIONS FOR IMPROVED PHARMACOKINETICS	201102458-5	
1914-56	SG	MPEX-052 SG DIV	AEROSOL FLUOROQUINOLONE FORMULATIONS FOR IMPROVED PHARMACOKINETICS	201307445-5	
1914-56	ZA	MPEX-052 ZA	AEROSOL FLUOROQUINOLONE FORMULATIONS FOR IMPROVED PHARMACOKINETICS	2011/03339	2011/03339
1914-57	BR		METHODS OF TREATING A PULMONARY BACTERIAL INFECTION USING FLUORO-QUINOLONES	PI1006626-8	
1914-57	WO		METHODS OF TREATING A PULMONARY BACTERIAL INFECTION USING FLUORO-QUINOLONES	PCT/US10/032128	
1914-57	US		METHODS OF TREATING A PULMONARY BACTERIAL INFECTION USING FLUORO-	61/172625	

Docket	Country	Internal Reference No.	Title	Serial No.	Patent No.
			QUINOLONES		
1914-58	WO		USE OF AEROSOLIZED LEVOFLOXACIN FOR TREATING CYSTIC FIBROSIS	PCT/US10/047903	
1914-58	US		USE OF AEROSOLIZED LEVOFLOXACIN FOR TREATING CYSTIC FIBROSIS	61/249231	
1914-58	US		USE OF AEROSOLIZED LEVOFLOXACIN FOR TREATING CYSTIC FIBROSIS	61/240092	
1914-59	CO	MPEX-059 CO	USE OF AEROSOLIZED LEVOFLOXACIN FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE	12-32808	
1914-59	US	MPEX-059 CON	USE OF AEROSOLIZED LEVOFLOXACIN FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE	13/398310	
1914-59	IL	MPEX-059 IL	USE OF AEROSOLIZED LEVOFLOXACIN FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE	218148	
1914-59	NZ	MPEX-059 NZ	USE OF AEROSOLIZED LEVOFLOXACIN FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE	598431	

Docket	Country	Internal Reference No.	Title	Serial No.	Patent No.
1914-59	WO	MPEX-059 PCT	USE OF AEROSOLIZED LEVOFLOXACIN FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE	PCT/US10/002307	
1914-59	US	MPEX-059 PRO	USE OF AEROSOLIZED LEVOFLOXACIN FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE	61/235319	
1914-59	US	MPEX-059 PRO 2	USE OF AEROSOLIZED LEVOFLOXACIN FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE	61/240749	
1914-59	US	MPEX-059 PRO 3	USE OF AEROSOLIZED LEVOFLOXACIN FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE	61/249228	
1914-60	US	MPEX-060	RIBOFLAVIN BASED AEROSOL AND USE AS PLACEBO IN TRIALS	13/398507	
1914-60	WO	MPEX-060 PCT	RIBOFLAVIN BASED AEROSOL AND USE AS PLACEBO IN TRIALS	PCT/US10/002306	
1914-66	AU	MPEX-057 AU	METHODS OF TREATING A PULMONARY BACTERIAL INFECTION USING FLUOROQUINOLONES	2010238765	2010238765
1914-66	BR	MPEX-057 BR	METHODS OF TREATING A PULMONARY BACTERIAL INFECTION USING	1811041078	

Docket	Country	Internal Reference No.	Title	Serial No.	Patent No.
			FLUOROQUINOLONE S		
1914-66	CA	MPEX-057 CA	METHODS OF TREATING A PULMONARY BACTERIAL INFECTION USING FLUOROQUINOLONE S	2759874	
1914-66	CL	MPEX-057 CL	METHODS OF TREATING A PULMONARY BACTERIAL INFECTION USING FLUOROQUINOLONE S	02649-2011	
1914-66	CN	MPEX-057 CN	METHODS OF TREATING A PULMONARY BACTERIAL INFECTION USING FLUOROQUINOLONE S	201080018022.0	
1914-66	CO	MPEX-057 CO	METHODS OF TREATING A PULMONARY BACTERIAL INFECTION USING FLUOROQUINOLONE S	11-148624	
1914-66	EP	MPEX-057 EP	METHODS OF TREATING A PULMONARY BACTERIAL INFECTION USING FLUOROQUINOLONE S	10767800.5	
1914-66	IL	MPEX-057 IL	METHODS OF TREATING A PULMONARY BACTERIAL INFECTION USING FLUOROQUINOLONE S	215777	

Docket	Country	Internal Reference No.	Title	Serial No.	Patent No.
1914-66	IN	MPEX-057 IN	METHODS OF TREATING A PULMONARY BACTERIAL INFECTION USING FLUOROQUINOLONES	8857/DELNP/2011	
1914-66	IN	MPEX-057 IN DIV	METHODS OF TREATING A PULMONARY BACTERIAL INFECTION USING FLUOROQUINOLONES	8857/DELNP/2011	
1914-66	JP	MPEX-057 JP	METHODS OF TREATING A PULMONARY BACTERIAL INFECTION USING FLUOROQUINOLONES	2012-507400	
1914-66	KR	MPEX-057 KR	METHODS OF TREATING A PULMONARY BACTERIAL INFECTION USING FLUOROQUINOLONES	10-2011-7027809	
1914-66	MX	MPEX-057 MX	METHODS OF TREATING A PULMONARY BACTERIAL INFECTION USING FLUOROQUINOLONES	MX/a/2011/011190	
1914-66	MY	MPEX-057 MY	METHODS OF TREATING A PULMONARY BACTERIAL INFECTION USING FLUOROQUINOLONES	PI2011005063	

Docket	Country	Internal Reference No.	Title	Serial No.	Patent No.
1914-66	NZ	MPEX-057 NZ	METHODS OF TREATING A PULMONARY BACTERIAL INFECTION USING FLUOROQUINOLONES	596245	596245
1914-66	NZ	MPEX-057 NZ DIV	METHODS OF TREATING A PULMONARY BACTERIAL INFECTION USING FLUOROQUINOLONES	616438	
1914-66	WO	MPEX-057 PCT	METHODS OF TREATING A PULMONARY BACTERIAL INFECTION USING FLUOROQUINOLONES	PCT/US10/32128	
1914-66	US	MPEX-057 PCT CON	METHODS OF TREATING A PULMONARY BACTERIAL INFECTION USING FLUOROQUINOLONES	13/278706	
1914-66	US		METHODS OF TREATING A PULMONARY BACTERIAL INFECTION USING FLUOROQUINOLONES	US 61/172,625	
1914-66	RU	MPEX-057 RU	METHODS OF TREATING A PULMONARY BACTERIAL INFECTION USING FLUOROQUINOLONES	2011145430	253056
1914-66	SG	MPEX-057 SG	METHODS OF TREATING A PULMONARY BACTERIAL	201107693-2	

Docket	Country	Internal Reference No.	Title	Serial No.	Patent No.
			INFECTION USING FLUOROQUINOLONES		
1914-66	SG	MPEX-057 SG DIV	METHODS OF TREATING A PULMONARY BACTERIAL INFECTION USING FLUOROQUINOLONES	10201403512T	
1914-66	VN	MPEX-057 VN	METHODS OF TREATING A PULMONARY BACTERIAL INFECTION USING FLUOROQUINOLONES	1-2011-03040	
1914-66	ZA	MPEX-057 ZA	METHODS OF TREATING A PULMONARY BACTERIAL INFECTION USING FLUOROQUINOLONES	2011/07903	2011/07903
1914-67	US		USE OF AEROSOLIZED LEVOFLOXACIN FOR TREATING CYSTIC FIBROSIS	61/240,092	
1914-67	US		USE OF AEROSOLIZED LEVOFLOXACIN FOR TREATING CYSTIC FIBROSIS	61/249,231	
1914-67	PCT		USE OF AEROSOLIZED LEVOFLOXACIN FOR TREATING CYSTIC FIBROSIS	PCT/US2010/047903	
1914-67	US	MPEX-058	USE OF AEROSOLIZED LEVOFLOXACIN FOR TREATING CYSTIC FIBROSIS	13/412423	
1914-67	AU	MPEX-058 AU	USE OF AEROSOLIZED LEVOFLOXACIN FOR TREATING CYSTIC	2010289326	

Docket	Country	Internal Reference No.	Title	Serial No.	Patent No.
			FIBROSIS		
1914-67	BR	MPEX-058 BR	USE OF AEROSOLIZED LEVOFLOXACIN FOR TREATING CYSTIC FIBROSIS	BR112012004692.6	
1914-67	CA	MPEX-058 CA	USE OF AEROSOLIZED LEVOFLOXACIN FOR TREATING CYSTIC FIBROSIS	2773033	
1914-67	CL	MPEX-058 CL	USE OF AEROSOLIZED LEVOFLOXACIN FOR TREATING CYSTIC FIBROSIS	00586-2012	
1914-67	CN	MPEX-058 CN	USE OF AEROSOLIZED LEVOFLOXACIN FOR TREATING CYSTIC FIBROSIS	201080048091.6	
1914-67	CO	MPEX-058 CO	USE OF AEROSOLIZED LEVOFLOXACIN FOR TREATING CYSTIC FIBROSIS	12-38470	
1914-67	EP	MPEX-058 EP	USE OF AEROSOLIZED LEVOFLOXACIN FOR TREATING CYSTIC FIBROSIS	10814595.4	
1914-67	IL	MPEX-058 IL	USE OF AEROSOLIZED LEVOFLOXACIN FOR TREATING CYSTIC FIBROSIS	218458	
1914-67	IN	MPEX-058 IN	USE OF AEROSOLIZED LEVOFLOXACIN FOR TREATING CYSTIC FIBROSIS	2477/DELNP/2012	
1914-67	JP	MPEX-058 JP	USE OF AEROSOLIZED LEVOFLOXACIN FOR TREATING CYSTIC FIBROSIS	2012-528109	

Docket	Country	Internal Reference No.	Title	Serial No.	Patent No.
1914-67	KR	MPEX-058 KR	USE OF AEROSOLIZED LEVOFLOXACIN FOR TREATING CYSTIC FIBROSIS	10-2012-7008678	
1914-67	MX	MPEX-058 MX	USE OF AEROSOLIZED LEVOFLOXACIN FOR TREATING CYSTIC FIBROSIS	MX/a/2012/002731	
1914-67	NZ	MPEX-058 NZ	USE OF AEROSOLIZED LEVOFLOXACIN FOR TREATING CYSTIC FIBROSIS	598484	598484
1914-67	RU	MPEX-058 RU	USE OF AEROSOLIZED LEVOFLOXACIN FOR TREATING CYSTIC FIBROSIS	2012111458	
1914-67	RU		USE OF AEROSOLIZED LEVOFLOXACIN FOR TREATING CYSTIC FIBROSIS	2015130524	
1914-67	ZA	MPEX-058 ZA	USE OF AEROSOLIZED LEVOFLOXACIN FOR TREATING CYSTIC FIBROSIS	2012/02434	2012/02434